鉅子生物(02367.HK)全球發售2260.88萬股 最終發售價定為每股24.3港元
格隆匯11月3日丨鉅子生物(02367.HK)發佈公吿,公司全球發售2260.88萬股股份,其中香港發售股份226.12萬股,國際發售股份2034.76萬股,另有15%超額配股權;最終發售價已釐定為每股發售股份24.30港元,每手買賣單位200股;高盛及中金公司為聯席保薦人;預期股份將於2022年11月4日於聯交所主板掛牌上市。
根據香港公開發售初步提呈發售的香港發售股份已獲輕微超額認購。合共接獲5450份有效申請,認購合共470.86萬股香港發售股份,相當於香港公開發售項下初步可供認購香港發售股份總數約2.08倍。國際發售項下初步提呈發售的發售股份已獲適度超額認購,相當於國際發售項下初步可供認購發售股份總數的約4.22倍。
假設超額配售權未獲行使,按每股最終發售價24.30港元計算,公司將收取的全球發售所得款項淨額估計約為4.958億港元。公司擬將所得款項淨額約11%用於研發投資以通過招聘擴大集團的研發團隊、擴展集團的研發設施及進行測試和驗證研究;約28%;預計將用於擴展與集團的產品組合及生物活性成分有關的生產能力;約46%預計將用於增強集團的全渠道銷售及經銷網絡,並開展以科學和知識為導向的營銷活動以提高集團的品牌知名度;約5%預計將用於提升集團運營及信息系統,包括採購軟件和硬件、通過對服務器及互聯網設備等硬件的投資開發一體化混合雲基礎設施及招聘IT專家,包括軟件開發人員及IT工程師;及約10%的所得款項淨額預計將用作營運資金及一般公司用途。假設超額配售權獲悉數行使,則集團將就超額配售權獲行使後將予發行的339.12萬股額外股份收取約7790萬港元的額外所得款項淨額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.